Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Dopaminergic medications used in the treatment of patients with Parkinson's disease are
associated with motor and non-motor behavioural side-effects, such as dyskinesias and …

Abstract l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …

Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in
Parkinson's disease (PD) patients. We divided hemiparkinsonian rats treated chronically …

In an attempt to define clinically relevant models of akinesia and dyskinesia in 6‐
hydroxydopamine (6‐OHDA)‐lesioned rats, we have examined the effects of drugs with high …

Abstract L-DOPA (l-3, 4-dihydroxyphenylalanine) remains the most effective drug for the
treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor …

Parkinson's disease (PD) is the second most common neurodegenerative disorder. Despite
its high frequency the etiology is still unclear; several lines of evidence show that an …

The molecular basis of l-3, 4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID),
one of the major hindrances in the current therapy for Parkinson's disease, is still unclear …

Animal models of neurological deficits are essential for the assessment of new therapeutic
options. It has been suggested that rats are not as appropriate as primates for the …

In order to assess the role of striatal dopamine (DA) afferents in l-DOPA-induced dyskinesia,
we have studied a large series of rats sustaining 2, 3, or 4 unilateral injections of 6 …